The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BEVATEM: Phase II study of bevacizumab (B) in combination with temozolomide (T) in patients (pts) with first-line metastatic uveal melanoma (MUM): Final results.
Sophie Piperno-Neumann
No relevant relationships to disclose
Vincent Servois
No relevant relationships to disclose
Francois-Clement Bidard
No relevant relationships to disclose
Pascale Mariani
No relevant relationships to disclose
Corine Plancher
No relevant relationships to disclose
Alhassane Diallo
No relevant relationships to disclose
Nora Vago-Ady
Employment or Leadership Position - Roche
Laurence Desjardins
No relevant relationships to disclose